BiotechTube
Biotika

Biotika

Bratislava, Europe - Other· Est.
biotika.eu.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $15M

Overview

Biotika is a long-established European API manufacturer with over 70 years of operational history, headquartered in Bratislava, Slovakia. Its core business is the biotechnological fermentation and production of established antibiotic APIs, specifically penicillin V and polymyxin B sulfate, which it exports globally. The company complements its proprietary manufacturing with contract development and manufacturing organization (CDMO) services, focusing on scale-up and process optimization for biotechnological products. Operating under stringent EU (EMA) and US (FDA) GMP standards, Biotika is a specialized, revenue-generating player in the generic antibiotic and niche anti-infective supply chain.

Infectious Disease

Technology Platform

Large-scale microbial fermentation and downstream processing for antibiotic production, with proprietary processes for polymyxin B sulfate. Offers technology transfer and scale-up services from lab to commercial scale.

Funding History

2
Total raised:$15M
Series A$12M
Grant$3M

Opportunities

The growing global health threat of antimicrobial resistance (AMR) sustains and increases demand for last-resort antibiotics like polymyxin B, for which Biotika has a proprietary process.
The trend towards outsourcing by biotech firms creates opportunities to expand its contract development and manufacturing (CDMO) services, leveraging its EU-based, GMP-compliant fermentation expertise.

Risk Factors

Significant regulatory risk as compliance with stringent FDA and EMA GMP standards is mandatory; any failure could halt production and exports.
The company faces competitive pressure from large-scale API producers and long-term market risks from antimicrobial stewardship and the potential development of new antibiotic classes.

Competitive Landscape

Biotika competes in the global generic API market, facing competition from large-scale producers in Asia and other regions on cost for products like penicillin. Its niche in polymyxin B production places it among a smaller group of specialized manufacturers. As a European CDMO for fermentation, it competes with other regional service providers on technical expertise, capacity, and regulatory track record.

More companies in Small Molecule Drugs →More companies in Europe - Other →